Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

NCT02561455 | Completed Phase 1 Results

• 1 other identifier: 2215-CL-0109
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 7

Brief Summary

The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study.

Conditions

Advanced Solid Tumors; Acute Myeloid Leukemia

Keywords

Advanced solid tumors; Acute myeloid leukemia; gilteritinib; ASP2215

Outcome Measures

Primary Outcomes (2)

• Number of Participants With Adverse Events

  AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator.

  From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 811.0 days, minimum of 43 days and maximum of 1067 days)

• Eastern Cooperative Oncology Group (ECOG) Performance Status at End Of Treattment Visit (EOT)

  ECOG performance status was used to assess participants disease progression, and ability to carry out the daily living activities. The participants were graded on a scale of 0 to 5 where 0 = fully active, able to carry on all predisease performance without restriction; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = capable of only limited self-care,confined to bed or chair more than 50% of waking hours; 4 = completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5 = Dead. Number of participants with ECOG performance status was reported.

  EOT Visit (30 days post-last dose, maximum treatement duration of 1067 days)

Study Arms (4)

Gilteritinib 40 mg

EXPERIMENTAL

Participants received gilteritinib 40 milligrams (mg) dose (one tablet of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

Drug: Gilteritinib

Gilteritinib 80 mg

EXPERIMENTAL

Participants received gilteritinib 80 mg dose (two tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

Drug: Gilteritinib

Gilteritinib 120 mg

EXPERIMENTAL

Participants received gilteritinib 120 mg dose (three tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

Drug: Gilteritinib

Gilteritinib 200 mg

EXPERIMENTAL

Participants received gilteritinib 200 mg dose (five tablets of 40 mg) orally once a day in continuous 28-day cycles at least 2 hours after or 1 hour before food. Gilteritinib treatment continued until participants no longer received clinical benefit from therapy, or unacceptable toxicity occured, or met one of the treatment discontinuation criteria.

Drug: Gilteritinib

Interventions

Gilteritinib DRUG

oral tablet

Also known as: ASP2215

Gilteritinib 120 mg; Gilteritinib 200 mg; Gilteritinib 40 mg; Gilteritinib 80 mg

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subject must currently be participating in an Astellas sponsored, single agent ASP2215 trial, receiving ASP2215 and have not met any discontinuation criteria of the parent study and can enroll into this rollover study without interruption of study drug, or with no more than 2 weeks interruption in study drug.
• Subject must be deriving benefit from continued treatment without any persistent intolerable toxicity from continued treatment of ASP2215.
• Female subject must either:
• Be of non-childbearing potential: post-menopausal (defined as at least 1 year without any menses) prior to Screening, or documented surgically sterile or post-hysterectomy (at least 1 month prior to Screening)
• Or, if of childbearing potential, Agree not to try to become pregnant during the study and for 180 days after the final study drug administration; And have a negative urine pregnancy test at Day 1; And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 180 days after the final study drug administration.
• Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 60 days after the final study drug administration.
• Female subject must not donate ova starting at Screening and throughout the study period, and for 180 days after the final study drug administration.
• Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 120 days after the final study drug administration.
• Male subject must not donate sperm starting at Screening and throughout the study period and, for 120 days after the final study drug administration.
• Subject agrees not to participate in another interventional study while on treatment.

You may not qualify if:

• Subject requires treatment with concomitant drugs that are strong inducers of cytochrome P450 (CYP)3A.
• Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.
• Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-glycoprotein (P-gp) with the exception of drugs that are considered absolutely essential for the care of the subject.

Sponsors & Collaborators

• Astellas Pharma Global Development, Inc.: lead

Study Sites (7)

Site US10005

Phoenix, Arizona, 85084, United States

Location

Site US10003

Baltimore, Maryland, 21201, United States

Location

Site US10006

New York, New York, 10032, United States

Location

Site US10007

New York, New York, 10065, United States

Location

Site US10001

Cleveland, Ohio, 44195, United States

Location

Site US10004

Hershey, Pennsylvania, 17033, United States

Location

Site US10008

Philadelphia, Pennsylvania, 19104, United States

Location

Related Links

• Link to results on the Astellas Clinical Study Results website.

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

gilteritinib

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Results Point of Contact

• Title: Clinical Trial Disclosure
• Organization: Astellas Pharma Global Development, Inc

astellas.resultsdisclosure@astellas.com

800-888-7704

Study Officials

• Executive Medical Director

  Astellas Pharma Global Development, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR
• Expanded Access: Yes

Study Record Dates

• First Submitted: September 25, 2015
• First Posted: September 28, 2015
• Study Start: May 3, 2016
• Primary Completion: July 28, 2020
• Study Completion: July 28, 2020
• Last Updated: November 19, 2024
• Results First Posted: August 16, 2021

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (7)